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ABSTRACT 
Objective 
 To study the association between lipid profile and liver  function test 
in type 2 diabetics.  
Methods 
 The study population consisted of 100  type 2 diabetic patients 
attending Diabetics clinic, Institute of non communicable diseases, 
Government Royapettah hospital, Government Kilpauk medical college, 
Chenna.FBS, PPBS, LFT, FLP and USG abdomen for detecting fatty 
liver were  done for all  paticipants.ALT /AST   > 30  and TC>200 
,TGL>150 were taken as elevated and their association with fatty liver 
was studied. Alcoholics with fatty liver were not included. 
Results 
 The  100 participants in the study included 49 females and 51 
males.Mean age was 52.6 +/- 10.426.).7 out of the 100 were alcoholics. 
73 of the total had raised ALT/AST.47 participants had raised TC and 
TGL.Both LFT and FLP were raised in 46 individuals. Out of the 71 
participants with elevated LFT (alcoholics excluded) 62 had fatty liver. 
43 of the 44 participants with elevated FLP had fatty liver..43 participants 
had all the 3 findings-elevated FLP,LFT and fatty liver in USG.Statistical 
analysis showed  there is significant association between FLP and LFT 
and FLP,LFT and fatty liver(p <0.01). 
Conclusion 
 There is significant association between FLP and LFT and FLP in 
type 2 diabetics. 
Keywords 
 Diabetes,Fasting lipid profile,Liver function test,Non alcoholic 
fatty liver disease,Ultrasonography 
Abbreviations 
 DM -Diabetes Mellitus,FLP -Fasting Lipid Profile,LFT-Liver 
Function Test,TC-Total Cholesterol,TGL –Triglycerides,AST-Aspartate 
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DM - Diabetes Mellitus 
FBS - Fasting Blood Sugar 
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3 
INTRODUCTION 
 Diabetes mellitus (DM)  is currently  defined as “a group of 
common metabolic  disorders that share the phenotype of 
hyperglycemia”. The prevalence of both type 1 and type 2 DM is 
increasing worldwide, the prevalence of type 2 DM  rising more rapidly, 
This is attributed  to increasing obesity, reduced activity levels , and the 
aging of the population. DM is expected to be  a leading cause of 
morbidity in the future due to its increasing incidence. 
 Multiple organ systems are affected due to the metabolic 
dysregulation associated with DM .Lipolysis and free fatty acid flux from 
adipocytes are increased, leading to increased lipid synthesis in 
hepatocytes due to insulin  resistance in adipocytes. This accounts  for  
the dyslipidemia found in type 2 DM . There is an association between 
diabetes and liver injury. Accumulation of glycogen in liver leads  to 
hepatomegaly and liver enzyme abnormalities in poorly controlled 
diabetes patients. 
 Nonalcoholic fatty liver disease (NAFLD) is frequently 
encountered in type 2 diabetic patients.NAFLD  represents a spectrum of 
histological findings from hepatic steatosis or fat accumulation in 
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hepatocytes to hepatic steatosis with a necroinflammatory component that 
may or may not have fibrosis, or NASH.  
 The lipid profile, liver function and  histopathological  changes in 
type 2 diabetic individuals are areas of active research.This study is 
aimed at studying the association of lipid profile and liver function in 
type 2 diabetic individuals –through FLP, LFT  and  USG for fatty liver, 
in individuals attending an Institute of Non-Communicable diseases at a 
tertiary care teaching hospital in Tamil Nadu, India. Information from this 
study could be of utility for protocol formation in the management and 
prevention of  diabetes and its  complications.  
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REVIEW OF LITERATURE 
 Diabetes mellitus(DM)  may be defined as “a group of common 
metabolic disorders that share the phenotype of hyperglycemia”.  DM 
includes distinct types that  are caused by  interaction between  genetic 
and environmental factors. Risk factors for hyperglycemia include 
reduced insulin secretion, decreased glucose utilization, and increased 
glucose production. Multiple organ systems are affected due to the 
metabolic dysregulation associated with DM causing secondary 
pathophysiologic changes. 
 DM is the leading cause of end-stage renal disease (ESRD), 
nontraumatic lower extremity amputations, and adult blindness in 
developed nations. 
 It also causes cardiovascular disease. DM is predicted to be  a 
leading cause of morbidity in the future due to its increasing incidence 
 The worldwide prevalence of DM is rising  dramatically, from an 
estimated 30 million cases in 1985 to 382 million in 2013 (Fig.1)  The 
International Diabetes Federation projects that 592 million individuals 
will have diabetes by the year 2035 based on current trends(1). 
7 
 
           Worldwide prevalence of diabetes mellitus. Global estimate is 382 
million individualswith diabetes. Regional estimates of the number of 
individuals with diabetes (20–79 years of age) are shown (2013). 
 The prevalence of both type 1 and type 2 DM is increasing 
worldwide, the prevalence of type 2 DM is rising more rapidly, due to 
increasing obesity, reduced activity levels , and the aging of the 
population.  The countries with maximum number of individuals with 
diabetes in 2013  were China (98.4 million), India (65.1 million), United 
States (24.4 million), Brazil (11.9 million), and the Russian Federation 
(10.9 million)(2). 80% of individuals with diabetes live in low-income or 
medium-income nations. It is estimated that about 50% of individuals 
with diabetes may be undiagnosed.  The incidence and prevalence of 
diabetes doubled from 1990–2008, but plateaued from 2008–2012. Also, 
there is  increase of DM  with age.The prevalence of DM was 26.9% in 
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those with age more than 65 years.Men and women throughout most age 
ranges (14% and 11% have the same prevalence.Most of the  individuals 
with diabetes are in the age group 40 to 59 years. 
 Also, there is significant  geographic variation in the incidence of 
type 1 and type 2 DM. Scandinavia has the highest incidence of type 1 
DM; the lowest incidence is in the Pacific Rim. Northern Europe and the 
United States have an intermediate rate.The  increased risk of type 1 DM 
may be due  to the increased frequency of high-risk human leukocyte 
antigen (HLA) alleles among ethnic groups in different geographic 
locations(3). The prevalence of type 2 DM and  IGT, is highest in Pacific 
islands and the Middle East, it is  intermediate in countries like  India and 
the United States. This variability is linked  to  various genetic, 
behavioral,and environmental factors. DM prevalence was observed to 
vary among different ethnic populations within a country, with 
indigenous populations  having a greater incidence of diabetes than the 
general population. in ethnic groups other than non-Hispanic whites,the 
onset of type 2 DM occurs at an earlier age. The prevalence of diabetes is 
increasing rapidly in Asia, and the diabetes phenotype is different from 
that in the United States and Europe, and the  onset is at a lower body 
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mass index (BMI) and younger age, greater visceral adiposity,and 
reduced insulin secretory capacity(4). 
 Diabetes is a major cause of mortality, but  studies indicate that 
diabetes is greatly underreported as a cause of death. Recent estimates 
give a picture that diabetes was responsible for almost5.1 million deaths 
or 8% of deaths worldwide in 2013. And  it was estimated that $548 
billion or 11% of health care expenditures worldwide were spent on 
individuals with diabetes in the year  2013. 
 The new classification of  DM is  on the basis of the pathogenic 
process that leads to Hyperglycemia. Earlier criteria was the age of onset 
or the type of therapy . There are two broad categories of DM, designated 
type 1 and type 2.  There are  other forms of diabetes in which the 
pathogenetic mechanisms are  different. 
1. “Type 1 diabetes (beta cell destruction  leading to  absolute insulin  
deficiency) 
A.  Immune-mediated 
B.  Idiopathic 
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2. Type 2 diabetes ( ranges  from predominantly insulin resistance 
with relative insulin deficiency to a predominantly insulin secretory 
defect with insulin resistance) 
3. Other specific types of diabetes 
A. Genetic defects of beta cell development or function 
characterized by mutations in: 
1. Hepatocyte nuclear transcription factor (HNF) 4α 
(MODY 1 
2. Glucokinase (MODY 2) 
3. HNF-1α (MODY 3) 
4. Insulin promoter factor-1 (IPF-1; MODY 4) 
5. HNF-1β (MODY 5 
6. NeuroD1 (MODY 6) 
7. Mitochondrial DNA 
8. Subunits of ATP-sensitive potassium channel 
9. Proinsulin or insulin 
10. Other pancreatic islet regulators/proteins such as 
KLF11, PAX4, BLK,GATA4 
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        B.  Genetic defects in insulin action 
1.  Type A insulin resistance  
2.  Leprechaunism 
3.  Rabson-Mendenhall syndrome 
4.  Lipodystrophy syndromes 
 C. Diseaes of the exocrine pancreas—pancreatitis, 
pancreatectomy, neoplasia, cystic fibrosis, hemochromatosis, 
fibrocalculous pancreatopathy 
 D. Endocrinopathies—acromegaly, Cushing’s syndrome,  
glucagonoma,pheochromocytoma, hyperthyroidism, 
somatostatinoma, aldosteronoma. 
 E. Drug- or chemical-induced—glucocorticoids, vacor  
(a rodenticide), pentamidine nicotinic acid, diazoxide,  
β-adrenergic agonists, thiazides,calcineurin and mTOR 
inhibitors, hydantoins, asparaginase, α-interferon,protease 
inhibitors, antipsychotics  (atypicals and others), epinephrine 
 F. Infections—congenital rubella, cytomegalovirus, 
coxsackievirus  
12 
 G. Uncommon forms of immune-mediated diabetes—”stiff-
person” syndrome, anti-insulin receptor antibodies 
 H. Other genetic syndromes sometimes associated with 
diabetes—Wolfram’s syndrome, Down’s syndrome, 
Klinefelter’s syndrome, Turners syndrome, Friedreich’s 
ataxia, Huntington’s chorea 
4. Gestational diabetes mellitus (GDM)” 
DIAGNOSIS 
 Glucose tolerance may be grouped in to 3 categories: normal 
glucose homeostasis, DM, or impaired glucose homeostasis. Fasting 
plasma glucose  (FPG), response to oral glucose challenge, or the 
hemoglobin A1c (HbA1c) is used to  assess the glucose 
tolerance(5).Normal glucose tolerance is considered as  An FPG <5.6 
mmol/L (100 mg/dL), a plasma glucose <140 mg/dL  (11.1 mmol/L) 
following an oral glucose challenge, and an HbA1c <5.7% Diagnostic 
criteria for DM has been issued by ADA, European Association for the 
Study of Diabetes, and the International Diabetes Federation on the 
following premises: 
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(1) "the FPG, the response to an oral glucose challenge (oral glucose 
tolerance test [OGTT]), and HbA1c differ among individuals, and 
 (2) DM is defined as the level of glycemia at which diabetes-specific 
complications occur rather than on deviations from a population-
based mean".  
 An FPG ≥7.0 mmol/L (126 mg/dL), a glucose ≥11.1 mmol/L (200 
mg/dL) 2 h after an oral glucose challenge, or an HbA1c ≥6.5% warrants 
the diagnosis of DM . A random plasma glucoseconcentration ≥11.1 
mmol/L (200 mg/dL) accompanied by classic symptoms of DM 
(polyuria, polydipsia, weight loss) is also sufficient for the diagnosis of 
DM. 
Abnormal glucose homeostasis  is defined as 
(1) FPG = 5.6–6.9 mmol/L (100–125 mg/dL), which is defined as 
impaired fasting glucose (IFG); 
(2) plasma glucose levels between 7.8 and 11 mmol/L (140 and 199 
mg/dL) following an oral glucose challenge, which is termed 
impaired glucose tolerance (IGT); or 
(3) HbA1c of 5.7–6.4%. 
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 The above  three groups are at greater risk of progressing to type 2 
DM, have an increased risk of cardiovascular disease, and should be 
counseled regarding  risk factor reduction. 
 “Some use the terms prediabetes, increased risk of diabetes, or 
intermediate hyperglycemia (World Health Organization) for this 
category”. The current criteria  emphasize the HbA1c or the FPG as the 
most reliable and   tests for identifying DM in asymptomatic individuals. 
 Abnormalities on screening tests for diabetes should be repeated 
before making a definitive diagnosis of DM. The  diagnosis of DM may 
be withdrawn in situations when the glucose intolerance reverts to 
normal. Use of the FPG or the HbA1c  as a screening test for the 
diadnosis of  type 2 DM is recommended because    
(1) a large number of  individuals who meet the current criteria for DM 
are asymptomatic  
(2) type 2 DM may be present for up to a decade before diagnosis as 
suggested by studies. 
(3) diabetes-specific complications may be present in some individuals  
at the time of their diagnosis, 
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(4) natural history of DM can be altered by early treatment, hence the 
diagnosis of prediabetes should spur efforts for diabetes 
prevention.  
  “As per ADA guidelines, screening of all individuals more than 45 
years every 3 years and screening individuals at an earlier age if they are 
overweight (BMI >25 kg/m2 or ethnically relevant definition  for 
overweight) and have one additional risk factor for diabetes  is 
recommended.” 
 Prior to the diagnosis of type 1,asymptomatic period is rare when 
compared to type 2 DM.Immunologic markers for the diagnosis of type  
1 DM are now  available . 
Criteria for the Diagnosis of Diabetes Mellitus 
• "Symptoms of diabetes plus random blood glucose concentration  
≥11.1 mmol/L (200 mg/dL) 
• Fasting plasma glucose ≥7.0 mmol/L (126 mg/dL) 
• Hemoglobin A1c ≥ 6.5% 
• 2-h plasma glucose ≥11.1 mmol/L (200 mg/dL) during an oral 
glucose tolerance test” 
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Risk Factors for Type 2 Diabetes Mellitus 
1. “Family history of diabetes (i.e., parent or sibling with type 2 
diabetes) 
2. Obesity (BMI ≥25 kg/m2 or ethnically relevant definition for 
overweight) 
3. Physical inactivity 
4. Race/ethnicity  
5. Previously identified with IFG, IGT, or an hemoglobin A1c of 5.7–
6.4% 
6. History of GDM or delivery of baby >4 kg (9 lb) 
7. Hypertension (blood pressure ≥140/90 mmHg) 
8. HDL cholesterol level <35 mg/dL (0.90 mmol/L) and/or a 
triglyceride level  >250 mg/dL (2.82 mmol/L) 
9. Polycystic ovary syndrome or acanthosis nigricans 
10. History of cardiovascular disease” 
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PATHOPHYSIOLOGY 
TYPE 1 DM 
 Complex  interactions of genetic, environmental,and immunologic 
factors causing destruction of the pancreatic beta cells and thus  insulin 
deficiency and type 1 DM. 
 The pancreatic islets are  infiltrated by  lymphocytes (a process 
termed insulitis) leading to their destruction and the islets become 
atrophic. The pathophysiologic process involves 
(1)  “islet cell autoantibodies;  
(2) activated lymphocytes in the islets, peripancreatic  lymph nodes, 
and systemic circulation;  
(3) T lymphocytes that proliferate when stimulated with islet proteins; 
and 
(4) release of cytokines within the insulitis”. 
  The autoimmune process is triggered by various environmental 
events. As the event may precede the onset of DM by several years,the 
identification of  environmental trigger is difficult. Possible  
18 
environmental triggers include viruses (coxsackie, rubella,enteroviruses ), 
nitrosourea compounds.bovine milk proteins etc. 
TYPE 2 DM 
 Pathophysiology of type 2 DM involves insulin resistance and 
abnormal insulin secretion. Most studies suggest  that insulin resistance 
precedes an insulin secretory defect but that diabetes develops only when 
insulin secretion becomes inadequate. 
The features of  Type 2 DM include   
i. “impaired insulin secretion, 
ii. insulin resistance,  
iii. excessive hepatic glucose production, 
iv. and abnormal fat metabolism” 
 Obesity, visceral or central , is very common in type 2 DM (≥80% 
of patients are obese).  Glucose tolerance  remains near-normal in early 
stages, despite insulin resistance, as  the pancreatic beta cells compensate 
by increasing insulin output. 
 The pancreatic islets are unable to sustain the hyperinsulinemic 
state as insulin resistance and compensatory hyperinsulinemia progress. 
19 
 This is manifested as development of IGT- elevations in 
postprandial glucose. overt diabetes with fasting hyperglycemia develops 
due to a further decline in insulin secretion and an increase in hepatic 
glucose production.  Beta cell failure ensues finally. 
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 Insulin resistance in the liver in type 2 DM reflects the failure of 
hyperinsulinemia to suppress gluconeogenesis, leading to fasting 
hyperglycemia and decreased glycogen storage by the liver in the 
postprandial state. 
 Increased hepatic glucose production occurs early in the course of 
diabetes.  
 Lipolysis and free fatty acid flux from adipocytes are increased, 
leading to increased lipid synthesis in hepatocytes due to insulin  
resistance in adipocytes. Nonalcoholic fatty liver disease  and abnormal 
liver function tests develop due to  lipid storage or steatosis in the 
liver.The same mechanism holds good for  the dyslipidemia found in type 
2 DM (elevated triglycerides, reduced high-density lipoprotein [HDL], 
and increased small dense low-density lipoprotein [LDL] ). 
LFT IN T2DM 
 There is an association between diabetes and liver injury(6). Liver 
helps in the regulation of carbohydrate homeostasis. Accumulation of 
glycogen in liver leads  to hepatomegaly and liver enzyme abnormalities 
in poorly controlled diabetes patients. In hyperglycemic states, there will 
be intracellular glycogen accumulation in the hepatocytes due to 
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increased glycogen synthesis,leading to mild to moderately elevated 
aminotransferases, normal liver  synthetic function, with or without mild 
elevations of alkaline phosphatase(7). The excess  free fatty acids found 
in the insulin-resistant state is  toxic to hepatocytes.Putative mechanisms 
include cell membrane disruption at high concentration, mitochondrial 
dysfunction, toxin formation, and activation and inhibition of key steps in 
the regulation of metabolism.(8) Other factors causing  elevated 
transaminases in insulin-resistant states include oxidant stress from 
reactive lipid peroxidation, peroxisomal beta-oxidation, and recruited 
inflammatory cells. The insulin-resistant state is also characterized by an 
increase in proinflammatory cytokines like tumor necrosis factor (TNF), 
which  contributes to hepatocellular injury(9).  It has been observed that 
the biochemical disturbances and hepatomegaly are reversible with good 
glycemic control. 
 Alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST) indicate the concentration of hepatic intracellular enzymes that 
have leaked into the circulation. Hence these are the markers for 
hepatocellular injury and are used as primary screening of 
NASH[10].Observation of  chronic mild elevations of ALT and AST has 
been seen in type 2 diabetes patients. Study done in United States by 
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Erbey et al in 2000 showed that  the prevalence of elevated ALT among 
type 2 diabetes is 7.8% compared to 3.8% in those without diabetes[11]. 
Again,another study by Salmela et al demonstrated that elevated ALT in 
diabetes patients was associated with increased BMI and poor glycemic 
control in multivariate  analysis[12]. Elevated liver enzymes are found to 
be predictors of future cardiovascular disease in some studies. Increased 
incidence of Cardiovascular Disease (CVD) was associated with raised 
gamma-GT of more than 40 U/L and AST of more than 40 U/L In the 
Firenze Bagno a Ripoli (FIBAR) study done in Italy.(12) 
Statins in Type 2 Diabetic Patients With Elevated 
Transaminases 
 In the Heart Protection Study of 20,536 high-risk individuals with 
vascular disease,  including individuals with diabetes,the rates of elevated 
ALT level above twice the upper limit of normal were 1.8% in the 
simvastatin group and 1.6% in the placebo group. This was not a 
significant difference.(13) In the Pravastatin in Elderly Individuals at 
Risk of Vascular Disease (PROSPER) trial,(14) only one patient in the 
pravastatin group and one patient in the placebo group had ALT or AST 
level above three times the upper limits of normal. There was no case of 
rhabdomyolysis. Myalgia was found in Thirty-six patients in the 
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pravastatin group  compared to 32 patients in the placebo group.High-
dose statin therapy may cause  frequent abnormalities of LFTs, though 
relatively infrequent. In the Treating to New Targets (TNT) trial,(15) 
patients with clinical cardiovascular disease (CVD) were randomized to 
10 or 80 mg of atorvastatin.The incidence of persistent elevation in ALT, 
AST, or both (defined as two consecutive measurements obtained 4–10 
days apart that were more than three times the upper limit of the normal 
range) was 0.2 and 1.2%, respectively (P < 0.001).(15) 
 The current recommendation of American College of Physicians is 
that type 2 diabetic  patients with other cardiovascular risk factors should 
take a statin for primary prevention  of macrovascular complications. 
These patients  need routine monitoring of LFTs while on statins if they 
have baseline abnormalities in LFTs, myopathy, or are taking other drugs 
that could increase their risk of adverse events.(16) For diabetic patients 
with baseline transaminases less than three times the upper limit of 
normal, statin therapy may be  initiated, continued, or advanced provided 
the patients are carefully monitored.(17) The frequency of required 
monitoring in these pati patients is under debate. There is also a debate as 
to whether transaminase elevation in statin therapy even constitutes true 
hepatitis.(17) 
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 In  diabetic patients above the age of 40 years, and  in the setting of 
multiple cardiovascular risk factors or known CVD, the potential risk of 
statin therapy from the perspective of hepatotoxicity is far outweighed by 
the proven benefit from CVD risk reduction. 
Oral Antidiabetic Agents in Type 2 Diabetic Patients With 
Elevated Transaminases 
 The insulin sensitizer troglitazone and it subsequently causing  
cases of hepatotoxicity led Jick et al.(18) to investigate the baseline risk 
of liver disease in type 2 diabetic patients on oral agents other than 
thiazolidinediones.(18) 
 In the study Oral antidiabetic agents could not be ruled out in two 
cases of liver disorder giving an incidence of 0.002/100 person-years. The 
idiosyncratic hepatic reaction leading to hepatic failure and death in some 
patients on troglitazone  was not found  to be a class effect of the 
peroxisomal proliferator-activated receptor-gamma agonists. 
 Rajagopalan et al.(19) performed a retrospective analysis of claims 
data comparing the incidence of liver failure in people with type 2 DM  
on pioglitazone versus other oral hypoglycemic agents. Over a 2-year 
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period,patients on pioglitazone had no increased risk of liver failure or 
hepatitis when compared to patients on the other antidiabetic agents. 
 The decrease in LFTs demonstrated with rosiglitazone and 
pioglitazone therapy in diabetic patients has also been shown in pilot 
studies using thiadolidinediones to treat NASH, a surrogate for insulin 
resistance. One study (20) placed 18 nondiabetic patients with NASH on 
pioglitazone, 30 mg daily, for 48 weeks. 
 By the end of the study, serum ALT levels  fell from an average of 
99 units/L at baseline to 40 units/L at 48 weeks. Another study(21) used 
rosiglitazone, 4 mg twice daily, for 48 weeks in the treatment of 30 
patients with NASH, 50% of whom had either impaired glucose tolerance 
or diabetes. Of the 25 patients who completed the study, all had 
significant improvements in mean serum ALT levels, changing from a 
baseline of 104 units/l to 42 units/l at 48 weeks. 
NAFLD IN T2DM 
 Nonalcoholic fatty liver disease (NAFLD) is the most common 
cause of elevated LFTs in type 2 diabetic patients.NA FLD  represents a 
spectrum of histological findings from hepatic steatosis or fat 
accumulation in hepatocytes without inflammation, to hepatic steatosis 
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with a necroinflammatory component that may or may not have fibrosis, 
or NASH. “NAFLD is defined by the absence of or minimal alcohol 
consumption, liver biopsy showing macrovesicular steatosis with or 
without necro-inflammatory activity, and exclusion of other forms of 
liver disease”.  it is characterized by accumulation of triglycerides within 
the hepatocytes. Insulin resistance  plays  an important role in the 
triglyceride accumulation. Excess intracellular fatty acids, oxidant 
stress,ATP depletion, and mitochondrial dysfunction all contribute to 
hepatocyte injury and inflammation followed by fibrosis(22).The most 
common laboratory abnormality in patients with NAFLD is mild to 
moderate elevation of serum aminotransferases. As in the histological 
study of diabetic patients with abnormal LFTs by Salmela et al.(23)  level 
of transaminase elevation in NAFLD does not predict severity of liver 
histology.(24) Raised ALT and AST are more common among the 
diabetes patients with higher BMI. AST elevation was also more common 
among men.  
NAFLD in Nondiabetic Patients 
 NAFLD is now the leading cause of chronically elevated LFTs in 
the United States in both diabetic and nondiabetic individuals.(25) Of 
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those patients with NAFLD, 60–95% are obese,28–55% have type 2 
diabetes, and 20–92% have hyperlipidemia. 
 In a prospective study of 1,124 adults who were referred for 
evaluation of chronically elevated LFTs, 81 were determined to have 
unknown etiology based on the  absence of serum markers for infectious 
(including hepatitis B and C), metabolic (thyroid-stimulating 
hormone),autoimmune (serum protein electrophoresis, antinuclear 
antibody, antimitochondri- al antibody, anti–smooth muscle antibody), or 
hereditary causes of liver disease (_-1 antitrypsin, ceruloplasmin, iron, 
iron-binding capacity, or ferritin).(26) They had no history of alcohol or 
hepatotoxic drug use nor signs of chronic liver disease. 
 In a similar study, 354 patients, both with and without diabetes, 
underwent liver biopsy to investigate abnormal LFTs. When patients with 
clinical or serological evidence of a specific diagnosis were excluded, 
66% of the patients had evidence of steatosis and steatohepatitis on 
biopsy.(27) 
Hepatitis C and Type 2 Diabetes 
 Hepatitis C virus (HCV), the leading cause of liver disease in the 
United States, is a known independent predictor of type 2 diabetes, the 
30 
most common endocrine disease even in patients without 
cirrhosis.(28,29) HCV has a higher prevalence within diabetic patients. 
This would suggest that any diabetic patient  with elevated LFTs needs 
screening for HCV . 
MANAGEMENT 
The goals of therapy for type 1 or type 2 diabetes mellitus (DM) are to 
(1) “eliminate symptoms related to hyperglycemia,  
(2) reduce or eliminate the long-term microvascular and 
macrovascular complications of DM, and  
(3) allow the patient to achieve as normal a lifestyle as 
possible.” 
 This is achieved by  identifying a target level of glycemic control 
for each patient, providing the patient with the educational and 
pharmacologic resources necessary to reach this level, and 
monitoring/treating  DM-related complications. Symptoms of diabetes 
usually resolve when the plasma glucose is <11.1 mmol/L(200 mg/dL), 
and thus most DM treatment focuses on achieving the second and third 
goals. 
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 The care of an individual with either type 1 or type 2 DM requires 
a multidisciplinary team. The most important aspect is patient’s 
participation, input, and enthusiasm. “Members of the health care team 
include the primary care provider and/or the endocrinologist or 
diabetologist, a certified diabetes educator, a nutritionist, and a 
psychologist”. In addition, when the complications of DM arise, 
subspecialists (including neurologists, nephrologists, vascular surgeons, 
cardiologists, ophthalmologists, and podiatrists) with experience in DM-
related complications are essential. In addition to the physical aspects of 
DM, social, family, financial, cultural, and employment-related issues 
need to be addressed. 
  “The International Diabetes Federation (IDF), recognizing that 
resources available for diabetes care vary widely throughout the world, 
has issued guidelines for “recommended care” (a well-developed service 
base and with health care funding systems consuming a significant part of 
their national wealth), “limited care” (health care settings with very 
limited resources), and “comprehensive care” (health care settings with 
considerable resources)”.  
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Guidelines for Ongoing, Comprehensive Medical Care for 
Patients with Diabetes 
1)  “Optimal and individualized glycemic control 
2)  Self-monitoring of blood glucose (individualized frequency) 
3)  HbA1c testing (2–4 times/year) 
4) Patient education in diabetes management (annual); 
diabetes-self management 
5)  education and support 
6)  Medical nutrition therapy and education (annual) 
7)  Eye examination (annual or biannual) 
8) Foot examination (1–2 times/year by physician; daily by 
patient;) 
9)  Screening for diabetic nephropathy (annual) 
10) Blood pressure measurement (quarterly) 
11) Lipid profile and serum creatinine (estimate GFR) (annual) 
12) Influenza/pneumococcal/hepatitis B immunizations 
13) Consider antiplatelet therapy” 
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Treat ment Goals for Adults with Diabetes 
1)  “Glycemic control 
2)  HbA1c <7.0% 
3) Preprandial capillary plasma glucose 4.4–7.2 mmol/L (80–
130 mg/dL) 
4) Peak postprandial capillary plasma glucose <10.0 mmol/L 
(<180 mg/dL) 
5) Blood pressure <140/90 mmHg Lipids  
6) Low-density lipoprotein <2.6 mmol/L (100 mg/dL) 
7) High-density lipoprotein >1 mmol/L (40 mg/dL) in men 
8) and >1.3 mmol/L (50 mg/dL) in Women 
9) Triglycerides <1.7 mmol/L (150 mg/dL)” 
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DETECTION AND PREVENTION OF COMPLICATIONS  
RELATED TO DIABETES 
 Timely and consistent surveillance procedures can reduce the 
morbidity and mortality rates of DM-related complications These 
screening procedures are indicated for all individuals with DM. A 
comprehensive eye examination should be performed by a qualified 
optometristor ophthalmologist. the American Diabetes Association 
(ADA) recommends the following ophthalmologic examination schedule:  
(1) type 1 DM-  an initial eye examination within 5 years of 
diagnosis, 
(2)  type 2 DM -an initial eye examination at the time of 
diabetes diagnosis. 
(3) women with DM who are pregnant or contemplating 
pregnancy - an    eye examination prior to conception and 
during the first trimester. 
(4) if eye exam is normal-repeat examination in 2–3 years. 
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PATIENT EDUCATION ABOUT DM, NUTRITION, AND 
EXERCISE 
 Education about nutrition, exercise, care of diabetes during illness, 
and medications to lower the plasma glucose should be given to all 
diabetic patients.This ensures  greater  compliance and responsibility.The 
ADA refers about this as diabetes self-management education(DSME) 
and diabetes self-management support (DSMS). DSME and DSMS  also 
emphasize psychosocial issues and emotional well-being of the patient. 
Diabetes Education  
 “A health care professional (nurse, dietician, or pharmacist) with 
specialized patient education skills who is certified in diabetes education 
may be called a diabetes educator.He/she covers topics like  
a. self-monitoring of blood glucose;  
b. urine ketone monitoring (type 1 DM);  
c. insulin administration; 
d. diabetes management during illnesses;  
e. prevention and management of hypoglycemia, 
f. foot and skin care;  
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g. diabetes management before, during, and after exercise; 
h. and risk factor–modifying activities.’ 
Psychosocial Aspects  
 Psychosocial assessment and treatment are a critical part of 
providing comprehensive diabetes care. It is important that the individual 
with DM accepts that he or she may develop complications related to 
DM. The patient is enabled to see him- or herself as an essential member 
of the diabetes care team and not as someone who is cared for by the 
diabetes management team. Emotional stress can lead to changes  in 
behavior and individuals no longer adhere to a dietary, exercise, or 
therapeutic regimen leading to uncontrolled blood sugars. 
Nutrition  
 “Medical nutrition therapy (MNT) is a term used by the ADA to 
describe the optimal coordination of caloric intake with other aspects of 
diabetes therapy (insulin, exercise, weight loss)”. MNT aims at 
preventing or delaying the onset of type 2 DM in high-risk individuals by 
promoting weight reduction-primary prevention. Secondary prevention- 
MNT tries to  prevent or delay diabetes-related complications in diabetic 
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individuals by improving glycemic control. Tertiary prevention – MNT 
manages diabetes-related complications. In selected patients, 
Pharmacologic approaches that facilitate weight loss and bariatric surgery 
are considered. the components of optimal MNT are similar for 
individuals with type 1 or type 2 DM and similar to those for the general 
population. 
 The MNT goal  in type 1 DM is to coordinate and match the caloric 
intake, both temporally and quantitatively, with the appropriate amount of 
insulin.  patients and providers should use carbohydrate counting or 
exchange systems to estimate the nutrient content of a meal or 
snack.depending on this  the bolus insulin dose for a meal or snack is 
determined. “MNT must be flexible enough to allow for exercise, and the 
insulin regimen must allow for deviations in caloric intake. An important 
component of MNT in type 1 DM is to minimize the weight gain often 
associated with intensive diabetes management”. 
 In type 2 DM,MNT focusses  on weight loss and addresses the 
greatly increased prevalence of cardiovascular riskfactors (hypertension, 
dyslipidemia, obesity) and disease in this population. 
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Exercise 
The  positive benefits of exercise include 
1. Cardiovascular risk reduction, 
2. reduced blood pressure, 
3. maintenance of muscle mass, 
4. reduction in body fat 
5. weight loss 
6. lowering plasma glucose and increasing insulin sensitivity. 
 ADA recommends 150 min/week (distributed over at least 3 days) 
of moderate aerobic physical activity with no gaps longer than 2 days in 
diabetics. The exercise regimen should also include resistance training. 
individuals with.DM lack the normal glucoregulatory mechanisms 
(normally,insulin falls and glucagon rises during exercise),hence exercise 
poses challenges too.“Individuals with type 1 DM are prone to either 
hyperglycemia or hypoglycemia during exercise, depending on the 
preexercise plasma glucose, the circulating insulin level, and the level of 
exercise-induced catecholamines. If the insulin level is too low,the rise in 
catecholamines may increase the plasma glucose excessively,promote 
ketone body formation, and possibly lead to ketoacidosis.Conversely, if 
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the circulating insulin level is excessive, this relative hyperinsulinemia 
may reduce hepatic glucose production (decreased glycogenolysis, 
decreased gluconeogenesis) and increase glucose entry into muscle, 
leading to hypoglycemia”. 
 Measures to avoid exercise-related hyper- or hypoglycemia in 
individuals with type 1 DM  
(1) “monitor blood glucose before, during, and after exercise; 
 (2) delay exercise if blood glucose is >14 mmol/L (250 mg/dL) and 
ketones are present; 
(3) if the blood glucose is <5.6 mmol/L (100 mg/dL), ingest 
carbohydrate before exercising;  
(4) monitor glucose during exercise and ingest carbohydrate to prevent  
hypoglycemia; 
 (5) decrease insulin doses (based on previous experience) before 
exercise and inject insulin into a nonexercising area 
(6)  learn individual glucose responses to different types of exercise 
and increase food intake for up to 24 h after exercise, depending on 
intensity a duration of exercise”. 
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 Exercise-related hypoglycemia is less common in type 2 diabetics 
but can occur in individuals taking  insulin or insulin secretagogues  
.Untreated proliferative retinopathy is a relative contraindication to 
vigorous exercise, as it can  lead ton vitreous hemorrhage or retinal 
detachment. 
MONITORING THE LEVEL OF GLYCEMIC CONTROL 
 This involves  plasma glucose measurements by the patient and an 
assessment of long-term control by the physician (measurement of 
hemoglobin A1c [HbA1c] and review of the patient’s self-measurements 
of plasma glucose)- the patient’s measurements  provide a picture of 
short-term glycemic control, whereas the HbA1c reflects average 
glycemic control over the previous 2–3 months. 
Self-Monitoring of Blood Glucose 
 “Self-monitoring of blood glucose (SMBG) is the standard of care 
in diabetes management and allows the patient to monitor his or her blood 
glucose at any time”.  
 They have maximum benefit  in individuals with hypoglycemia 
unawareness, frequent hypoglycemia and  those with underachieved 
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glycemic targets .  CGM  also has a role in the intensive care unit (ICU) 
setting. 
Assessment of Long-Term Glycemic Control 
 Measurement of glycated hemoglobin (HbA1c) is the standard 
method for assessing long-term glycemic control.It reflects the glycemic 
history over the previous 2–3 months as the erythrocytes have an average 
life span of 120 days .It is noteworthy that glycemic level in the 
preceding month contributes about 50% to the HbA1c value. 
PHARMACOLOGIC TREATMENT OF DIABETES 
Comprehensive care of type 1 and type 2 DM  emphasizes on 
i. exercise,  
ii. nutrition, 
iii. and monitoring of glycemic control  
iv. glucose-lowering medication(s). 
  The initial step is to select an individualized, glycemic goal for the 
patient and start the oral hypoglycemic agent/insulin and tapering the 
dose as per sugar values. 
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ESTABLISHMENT OF TARGET LEVEL OF GLYCEMIC 
CONTROL 
 All  the complications of DM are related to glycemic control.Hence  
normoglycemia or near-normoglycemia is the desired goal for most 
patients.  Factors to consider include the 
a. patient’s age  
b. ability to understand and implement a complex treatment 
regimes 
c. presence and severity of complications of diabetes, 
d. known cardiovascular disease (CVD), 
e. ability to recognize hypoglycemic symptoms, 
f. presence of other medical conditions or treatment 
g. lifestyle and occupation 
h.  level   of support available from family and friends. 
 ADA recommendation  is to achieve an HbA1c as close to normal 
as possible without significant hypoglycemia. In most individuals, the 
target HbA1c is  <7% with a more stringent target for selected patients. 
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 The frequency and severity of hypoglycemia is a concern, because 
this becomes more common with a more stringent HbA1c goal. 
 Large clinical trials (UKPDS, Action to Control Cardiovascular 
Risk in Diabetes [ACCORD], Action in Diabetes and Vascular 
Disease.Preterax and Diamicron MR Controlled Evaluation 
[ADVANCE],Veterans Affairs Diabetes Trial [VADT];  have examined 
glycemic control in type 2 DM in individuals with low risk of CVD,with 
high risk of CVD, or with established CVD and have found that more 
intense glycemic control is not beneficial and, in some patient 
populations, may have a negative impact on some outcomes(30). Hence 
there is a need for individualized glycemic goals based on the following 
general guidelines: 
(1) “early in the course of type 2 diabetes when the CVD risk is lower, 
improved glycemic control likely leads to improved cardiovascular 
outcome, but this benefit occurs more than a decade after the 
period of improved glycemic control;” 
(2) ”intense glycemic control in individuals with established CVD or 
at high risk for CVD is not advantageous, and may be deleterious, 
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over a follow-up of 3–5 years; an HbA1c goal <7.0% is not 
appropriate in this population;” 
(3) "hypoglycemia in such high-risk populations (elderly, CVD) 
should be avoided;” 
(4) “improved glycemic control reduces microvascular complications 
of diabetes  even if it does not improve macrovascular 
complications like CVD”. 
TREATMENT OF NAFLD 
Treatment of NAFLD involves three aspects:  
(1) “specific therapy of NAFLD-related liver disease;  
(2) treatment of NAFLD associated comorbidities; and 
(3) treatment of the complications of advanced NAFLD.”   
 There are no FDA-approved therapies for the treatment of NAFLD 
at present. Hence  the current approach to NAFLD management focuses 
on treatment to improve the risk factors for NASH-obesity, insulin 
resistance, metabolic syndrome, dyslipidemia. only patients with NASH 
or those with features of hepatic fibrosis on liver biopsy are considered 
currently for targeted pharmacologic therapies. This approach may 
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change in future  as our understanding of disease pathophysiolog 
improves and potential targets of therapy evolve. 
Diet and Exercise  
 Lifestyle changes and dietary modification remain the cornerstone 
of NAFLD treatment.Studies prove  that lifestyle modification  improves 
serum aminotransferases and hepatic steatosis, with loss of at least 3–5% 
of body weight improving steatosis,and  weight loss up to 10%  improves 
steatohepatitis. 
 The beneficiary effects of various dietary macronutrient contents 
like low-carbohydrate vs low-fat diets, saturated vs unsaturated fat diets 
and different intensities of calorie restriction appear to be comparable. 
 Exercise regimens that improve fitness  reduces hepatic steatosis, 
but their impact on other aspects of liver histology remains unknown. 
Pharmacologic therapies such as orlistat, topiramate, and phentermine 
facilitate weight loss but their role in the treatment of NAFLD remains 
experimental. 
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Pharmacologic Therapies 
 Several drug therapies are being evaluated in both research and 
clinical settings. At present no agent has  been approved by the FDA for 
the treatment of NAFLD. 
1) Due to the  strong  association between NAFLD  and  metabolic 
syndrome and type 2 diabetes, the efficacy of various insulin-
sensitizing agents has been examined.   
a. Metformin (  TONIC study). that acts by  improving  hepatic 
insulin sensitivity, has been evaluated in several  studies in 
adults and a recent larger prospectively randomized trial in 
children (dubbed the TONIC study).Adult NASH studies 
suggested improvements in aminotransferases and/or liver 
histology, metformin did not improve liver histology in the 
TONIC study of children with NASH. Hence it is not 
currently recommended as a treatment for NASH. 
 b. Thiazolidinediones (pioglitazone and rosiglitazone) the 
PIVENs Study  (Pioglitazone vs Vitamin E vs Placebo for 
the Treatmentof 247 Nondiabetic   Adults with NASH)  are 
examples that acts by  improving  hepatic insulin sensitivity, 
has been evaluated in several  studies in adults and a recent 
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larger, prospectively randomized trial in children (dubbed 
the TONIC study). Adult NASH studies suggested 
improvements in aminotransferases and/or liver histology, 
metformin did not improve liver histology in the TONIC 
study of children with NASH. Hence it is not currently 
recommended as a treatment for NASH. 
2) Antioxidants are thought to have a role in the treatment of NAFLD 
because oxidant stress  contributes  to the pathogenesis of NASH.      
Vitamin E  was well tolerated, and most studies showed modest 
improvements in aminotransferase levels, radiographic features of 
hepatic steatosis, and/or histologic features of NASH.  
3) Ursodeoxycholic acid and betaine (metabolite that decreases 
cellular oxidative  damage) offer no histologic benefit over placebo 
in patients with NASH. 
4) Experimental evidence to support the use of omega-3 fatty acids in 
NAFLD exists;   however, a recent large, multicenter, placebo-
controlled study failed to demonstrate a histologic benefit.  
5) Other drugs  being evaluated in NAFLD  includes – 
i.  probiotics,  
ii. farnesoid Xreceptor agonists, 
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iii. anticytokine agents,  
iv. glucagon-like peptide agonists, 
v. dipeptidyl IV antagonists.  
6) Statins 
 These  are used to treat dyslipidemia and they decrease 
cardiovascular risk. There is currently  no evidence proving  that statins 
cause liver failure in patients with  chronic liver disease, including 
NAFLD.  Studies have suggested that statins may improve 
aminotransferases and histology in patients with NASH. 
Bariatric Surgery 
 Bariatric surgery is yet another treatment option for NAFLD. Most 
studies have shown that bariatric surgery is generally safe in individuals 
with well compensated chronic liver disease and improves hepatic 
steatosis and necroinflammation - features of NAFLD/NASH.But certain  
prospective studies suggest that hepatic fibrosis might progress after 
bariatric surgery. Hence  the Cochrane review deemed it premature to 
recommend bariatric surgery as a primary treatment for NASH.Also, 
patients with NAFLD related cirrhosis and portal hypertension are  
excluded as candidates for bariatric surgery.To sum up,given the  
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growing evidence for the benefits of bariatric surgery on metabolic 
syndrome complications in individuals with refractory obesity, bariatric 
surgery  is not contraindicated in otherwise eligible patients with NAFLD 
or NASH. 
Liver Transplantation  
 NAFLD patients in whom end-stage liver disease develops are 
candidates for liver transplantation. ‘The outcomes of liver  
transplantation in well-selected patients  with NAFLD are generally good, 
but comorbid  medical conditions associated with NAFLD, such as 
diabetes mellitus, obesity, and cardiovascular disease, often limit 
transplant candidacy”. NAFLD can  recur after liver transplantation.The 
risk factors for recurrent or de novo NAFLD after liver transplantation 
are multifactorial - 
 a. hypertriglyceridemia,  
           b. obesity, 
           c. diabetes mellitus,  
           d. and immunosuppressive therapies, particularly 
glucocorticoids. 
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AIM OF THE STUDY 
 To study the association between lipid profile and liver function 
tests in type 2 diabetic patients. 
 Early diagnosis of NAFLD and reversal/ prevention of progression 
to NASH,Cirrhosis and liver malignancy 
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MATERIALS AND METHOD 
Study design 
 Descriptive cross sectional study. 
Study period 
 6 months. 
Study area 
 Tertiary health care centre. 
Study population 
 Type 2 diabetic patients attending diabetology OP, tertiary health 
care centre. 
Conflict of interest 
 nil 
Sample Size 
 Calculated using formula  4pq/d2          
 p=prevalence(56%)  q=(1-P)  d=precision(20% of P) =100 
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Ethical clearance 
 Ethical committee clearance was obtained. 
Consent 
 Informed consent obtained from all subjects.Patient confidentiality 
maintained. 
Inclusion criteria  
 Type 2  diabetic patients with age >32yrs attending diabetology op 
in a tertiary care centre. 
Exclusion criteria 
 No exclusion criteria as the aim of the study is to find the 
association between lipid profile,LFT and diabetes. 
Data analysis 
 Data was  collected using predesigned proforma. The study 
population consisted of 100 non-hospitalised diabetic patients, both males 
and females of  age >35 years, who attended diabetology 
op.FBS,PPBS,LFT and FLP were done. USG abdomen for detecting fatty 
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liver was also done for all  patients.ALT and AST value of more than 30  
and TC>200 ,TGL>150 as elevated and their association with fatty liver 
was studied.Alcoholics with fatty liver were not included. 
STATISTICS 
 The collected data were analysed with IBM.SPSS statistics 
software 23.0 Version. To describe about the data descriptive statistics 
frequency analysis, percentage analysis were used for categorical 
variables and the mean & S.D were used for continuous variables. To  
find the association in the categorical data Fisher's exact test was used. In 
the above statistical tools the probability value .05 is considered as 
significant level. 
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RESULTS 
 There were 100 participants in the study. Mean age was 52.6 +/- 
10.426(table 7).There were 49 females and 51 males.(table 1).7 out of the 
100 were alcoholics. 
 Table 4 shows 73 of the total had raised ALT/AST.47 participants 
had raised TC and TGL-depicted in table 5.Both LFT and FLP were 
raised in 46 individuals as shown in table 6.Figure 2 shows the 
association between LFT and FLP. 
 Out of the 71 participants with elevated LFT (alcoholics excluded) 
62 had fatty liver.Table 8 depicts this.Figure 3 shows this association. 
 43 of the 44 participants with elevated FLP had fatty liver. This is 
demonstrated in table 9.Figure 4 shows the pictorical representation. 
 Table 10 shows the data  on  association between FLP,LFT and 
Fatty liver in USG.43 participants had all the 3 findings.Fishers exact test 
shows significant association-table 11.Figure 5 gives the pictorical 
representation. 
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Table.1 
SEX 
 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid Female 49 49.0 49.0 49.0 
Male 51 51.0 51.0 100.0 
Total 100 100.0 100.0   
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Table.2 
ALCOHOLISM 
 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid Absent 93 93.0 93.0 93.0 
Present 7 7.0 7.0 100.0 
Total 100 100.0 100.0   
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Table.3 
USG-FATTY LIVER 
 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid Absent 30 30.0 32.3 32.3 
Present 63 63.0 67.7 100.0 
Total 93 93.0 100.0   
Missing 0 7 7.0     
Total 100 100.0     
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Figure.1 
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Table.4 
LFT 
 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid Negative 27 27.0 27.0 27.0 
Positive 73 73.0 73.0 100.0 
Total 100 100.0 100.0   
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Table.5 
FLP 
 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid Negative 53 53.0 53.0 53.0 
Positive 47 47.0 47.0 100.0 
Total 100 100.0 100.0   
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Table.6 
LFT & FLP 
 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid Negative 54 54.0 54.0 54.0 
Positive 46 46.0 46.0 100.0 
Total 100 100.0 100.0   
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Figure.2 
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Table.7 
Descriptive Statistics 
 
N Minimum Maximum Mean 
Std. 
Deviation 
AGE  100 33 82 52.16 10.426 
FBS 100 74 234 116.23 26.339 
PPBS 100 100 298 169.52 32.535 
TC 100 152 344 210.47 31.921 
TGL 100 88 198 139.66 29.398 
TP 100 5.0 8.0 6.390 .7263 
ALB  100 3.0 5.0 3.865 .4604 
GLB  100 2.0 3.5 2.530 .4781 
BIL 100 .5 66.0 2.573 8.9631 
ALT  100 18 88 42.30 13.475 
AST 100 18 96 44.11 14.728 
Valid N 
(listwise) 
100         
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Table.8 
Crosstab 
 
USG-FL 
Total 
Absent Present 
LFT Normal LFT Count 21 1 22 
% within 
USG-FL 
70.0% 1.6% 23.7% 
Elevated 
LFT 
Count 9 62 71 
% within 
USG-FL 
30.0% 98.4% 76.3% 
Total Count 30 63 93 
% within 
USG-FL 
100.0% 100.0% 100.0% 
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Chi-Square Tests 
 
Value df 
Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Pearson Chi-
Square 
52.667a 1 .000     
Continuity 
Correctionb 
48.947 1 .000     
Likelihood 
Ratio 
54.835 1 .000     
Fisher's Exact 
Test 
      .0005 .000 
N of Valid 
Cases 
93         
a. 0 cells (0.0%) have expected count less than 5. The minimum expected 
count is 7.10. 
b. Computed only for a 2x2 table 
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Figure 3 
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Table.9 
Crosstab 
 
USG-FL 
Total 
Absent Present 
FLP Normal FLP Count 29 20 49 
% within 
USG-FL 
96.7% 31.7% 52.7% 
Elevated 
FLP 
Count 1 43 44 
% within 
USG-FL 
3.3% 68.3% 47.3% 
Total Count 30 63 93 
% within 
USG-FL 
100.0% 100.0% 100.0% 
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Chi-Square Tests 
 
Value df 
Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Pearson Chi-
Square 
34.361a 1 .000     
Continuity 
Correctionb 
31.806 1 .000     
Likelihood 
Ratio 
41.145 1 .000     
Fisher's Exact 
Test 
      .0005 .000 
N of Valid 
Cases 
93         
a. 0 cells (0.0%) have expected count less than 5. The minimum expected 
count is 14.19. 
b. Computed only for a 2x2 table 
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Figure.4 
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Table.10 
Crosstab 
 
USG-FL 
Total 
Absent Present 
LFT & 
FLP 
+VE 
Normal Count 29 20 49 
% within 
USG-FL 
96.7% 31.7% 52.7% 
Elevated 
LFT & FLP 
Count 1 43 44 
% within 
USG-FL 
3.3% 68.3% 47.3% 
Total Count 30 63 93 
% within 
USG-FL 
100.0% 100.0% 100.0% 
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Chi-Square Tests 
 
Value df 
Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Pearson Chi-
Square 
34.361a 1 .000     
Continuity 
Correctionb 
31.806 1 .000     
Likelihood 
Ratio 
41.145 1 .000     
Fisher's Exact 
Test 
      .0005 .000 
N of Valid 
Cases 
93         
a. 0 cells (0.0%) have expected count less than 5. The minimum expected 
count is 14.19. 
b. Computed only for a 2x2 table 
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Figure.5 
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DISCUSSION 
The main findings of the study are as follows:- 
1. Type 2 diabetic patients are prone to elevations in lipid profile. 
2. Individuals with Type 2 diabetes have a higher incidence of LFT 
abnormalities than  non diabetic individuals. 
3. There is higher incidence of fatty liver in type  2 diabetics. 
4. Derangement of FLP and LFT has statistically significant 
correlation with fatty liver. 
 Diabetes mellitus (DM)  may be defined as “a group of common 
metabolic disorders that share the phenotype of hyperglycemia”. The 
prevalence of both type 1 and type 2 DM is increasing worldwide, the 
prevalence of type 2 DM is rising more rapidly, due to increasing obesity, 
reduced activity levels , and the aging of the population. DM is predicted 
to be  a leading cause of morbidity in the future due to its increasing 
incidence. 
 Multiple organ systems are affected due to the metabolic 
dysregulation associated with DM causing secondary pathophysiologic 
78 
changes.Lipolysis and free fatty acid flux from adipocytes are increased, 
leading to increased lipid synthesis in hepatocytes due to insulin  
resistance in adipocytes. This accounts  for  the dyslipidemia found in 
type 2 DM (elevated triglycerides, reduced high-density lipoprotein 
[HDL], and increased  low-density lipoprotein. There is an association 
between diabetes and liver injury (30).  
 Liver helps in the regulation of carbohydrate homeostasis. 
Accumulation of glycogen in liver leads  to hepatomegaly and liver 
enzyme abnormalities in poorly controlled diabetes patients. It has been 
observed that the biochemical disturbances and hepatomegaly are 
reversible with good glycemic control. 
 Nonalcoholic fatty liver disease (NAFLD) is frequently 
encountered in type 2 diabetic patients.NAFLD  represents a spectrum of 
histological findings from hepatic steatosis or fat accumulation in 
hepatocytes without inflammation, to hepatic steatosis with a 
necroinflammatory component that may or may not have fibrosis, or 
NASH.  NAFLD management focuses on treatment to improve the risk 
factors for NASH-obesity, insulin resistance, metabolic syndrome and 
dyslipidemia. 
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 In our study, 100  type 2 DM patients of age more than 32 years 
were included. The mean age of the study population was 52.96.Out of 
100 total patients, 51 were females and 49 were males.7 out of the total 
100 patients were alcoholics. 
 In our study, 47 participants out of 100 (47%) were found to have 
raised FLP.A study conducted by Swaminathan S et al (31) had similar 
results.Many other multicenter studies have also proved the increased 
occurrence of dyslipidemia in type 2 diabetes. 
 Individuals  found to have an elevated LFT (ALT/AST) in the 
current study were 73 out of 100 (73%).The study by Samela et al (32) 
showed 57%  diabetics without any chronic liver disease had elevated 
LFT. An  Iranian cross sectional study demonstrated a rise of ALT and 
AST in 10.4% and 3.3% of type 2 diabetes patients respectively(33). In a 
UK cohort study of 959 diabetic patients over four year period, 15.7% 
had raised ALT, 10.4% had elevated alkaline phosphatase whereas only 
3.9% had hyperbilirubinaemia(34). 
 The present study showed that 63 out of 100  (63%)  had fatty liver 
in USG. This was after excluding the alcoholics with fatty liver. A large 
cohort study done in India reported the presence of fatty infiltration of 
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liver in ultrasonography in 62.25% (127 out of 204 diabetes 
patients)[(35). Another study done in Myanmar revealed presence of fatty 
liver in 16 % of diabetes patients on ultrasound scan(36). 
 The association between FLP and LFT,FLP and fatty liver,LFT and 
fatty liver and FLP,LFT and fatty liver was determined in our study.Out 
of the 47 patients with elevated FLP,46 had raised LFT also.Of the 44 
participants with elevated FLP(alcoholics excluded) 43 had fatty 
liver.The p value was found to be significant.Out of the 71 patients with 
elevated LFT (alcoholics excluded),62 had fatty liver in USG.Also the p 
value for the association between FLP,LFT and fatty liver was found to 
be significant. 
 The merit of this study is that it is an eye opener in to the 
association in type 2 DM between FLP and LFT.In addition,it also shows 
the association between fatty liver, FLP and LFT.  Based on the above 
observations,it could be recommended that routine monitoring of LFT 
,FLP and  USG for fatty liver  in patients with type 2 diabetes should 
occur at the start of drug therapy  to screen the possibility of underlying 
fatty liver, which might need further evaluation and early intervention to 
prevent from progression into cirrhosis and chronic liver disease and  
periodic screening thereafter based on clinical judgment. 
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 There are some limitations for our study. Our study, being a cross 
sectional one, could not address the effect of glycemic control over 
FLP,LFT and fatty liver. Although, alcoholics with fatty liver were 
excluded, other risk factors  like viral hepatitis, hemochromatosis, drugs 
etc. were not taken into account. However, we believe this is a valuable 
addition because of the scope for early intervention to prevent from 
progression of fatty liver into cirrhosis and chronic liver disease through 
monitoring of  FLP, LFT and fatty liver. 
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                                  CONCLUSION 
1 Type 2 diabetic patients are prone to elevations in lipid profile. 
2. Individuals with Type 2 diabetes have a higher incidence of LFT 
abnormalities than non diabetic individuals. 
3. There is higher incidence of fatty liver in type  2 diabetics. 
4. Derangement of FLP and LFT has statistically significant 
correlation with fatty liver. 
          The prevalence of both type 1 and type 2 DM is increasing 
worldwide, the prevalence of type 2 DM is rising more rapidly. 
Dyslipidemia,liver enzyme abnormalities and Nonalcoholic fatty liver 
disease (NAFLD) is frequently encountered in type 2 diabetic patients. 
With good glycemic control and regular  monitoring of FLP,LFT and 
fatty liver, there is scope for prevention  from progression of fatty liver 
into cirrhosis and chronic liver disease. Hence routine monitoring of LFT  
and USG for faty liver along with flp in patients with type 2 diabetes 
should occur at the start of drug therapy. 
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PROFORMA 
 
Name:                                                     Age/sex:                                             
Address:                                                  IP NO/OP NO: 
DM – Yes/No 
Diagnosis: 
BMI: 
QUESTIONNAIRE: 
Kuppusamy Socio economic State: 
Family History of DM / hypertension : 
Do you exercise regularly : 
Diet restriction : 
INVESTIGATIONS: 
Complete blood count  
Renal function tests 
Liver function tests 
Lipid profile – Triglycerides and Total Cholesterol 
Fasting Blood sugar  
Electrocardiogram 
Usg abdomen 
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பங்குபபறுபவரின்  வயது :                     பங்குபபறுபவரின்  எண் : 
மேமே குறிப்பிட்டுள்ள ேருத்துவ ஆய்வின் விவரங்கள் எனக்கு 
விளக்கப்பட்டது.  நான் இவ்வாய்வில் தன்னிச்சையாக பங்மகற்கிமறன்.                
சுயஒப்புதல் படிவம் 
ஆய்வு பைய்யப்படும் தசேப்பு: அறுசவ ைிகிச்சைக்குப் பின்னரான 
எேக்ட்மராகார்டிமயாகிராம் ோற்றங்கள் 
இடம்:            பபாது ேருத்துவத்துவ துசற 
  அரசு  கீழ்பாக்கம் ேருத்துவ கல்லூரி ேருத்துவேசன 
                         பைன்சன 
பங்குபபறுபவரின்  பபயர் : 
எந்த காரணத்தினாமோ எந்த ைட்டைிக்கலுக்கும் உட்படாேல் நான் 
இவ்வாய்வில் இருந்து விேகிக்பகாள்ளல்ோம் என்றும் அறிந்து பகாண்மடன். 
இந்த ஆய்வு ைம்பந்தோகமவா,  இசத ைார்ந்து மேலும் ஆய்வு 
மேற்பகாள்ளும்மபாதும் இந்த ஆய்வில்பங்கு பபறும் ேருத்துவர் என்னுசடய 
ேருத்துவ அறிக்சககசள பார்ப்பதற்கு என் அனுேதி மதசவயில்சே என 
அறிந்து பகாள்கிமறன்.  இந்த ஆய்வின் மூேம் கிசடக்கும் தகவசேமயா, 
முடிசவமயா பயன்படுத்திக்பகாள்ள ேறுக்க ோட்மடன். 
இந்த ஆய்வில் பங்கு பகாள்ள ஒப்புக்பகாள்கிமறன்.   இந்த ஆய்சவ 
மேற்பகாள்ளும் ேருத்துவ அணிக்கு உண்சேயுடன் இருப்மபன் என்றும் 
உறுதியளிக்கிமறன். 
பங்மகற்பவரின்   சகபயாப்பம்                           ஆய்வாளரின்   சகபயாப்பம் 
இடம் : 
மததி : 
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                                      PATIENT CONSENT FORM 
Study detail:    “A study of post-operative electrocardiographic changes in type 
2 diabetes patients.” 
Study centre : GOVERNMENT ROYAPETTAH HOSPITAL, 
CHENNAI 
Patients Name : 
Patients Age : 
Identification Number   : 
   Patient may check (     ) these boxes 
I  confirm that I have understood the purpose of procedure for the above study. 
I have the opportunity to ask question and all my questions and doubts have 
been answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being 
affected. 
I understand that sponsor of the clinical study, others working on the sponsor’s 
behalf, the ethical committee and the regulatory authorities will not need my 
permission to look at my health records, both in respect of current study and 
any further research that may be conducted in relation to it, even if I withdraw 
from the study I agree to this access. However, I understand that my identity 
94 
will not be revealed in any information released to third parties or published, 
unless as required under the law. I agree not to restrict the use of any data or 
results that arise from this study. 
I agree to take part in the above study and to comply with the instructions given 
during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my 
health or well-being or any unexpected or unusual symptoms. 
I hereby consent to participate in this study. 
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including hematological, biochemical, radiological tests. 
 
Signature/thumb impression:  
Patients Name and Address:                   place   date 
Signature of investigator :   
Study investigator’s Name :                      place   date      
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ஆராய்ச்ைி தகவல் 
 பைன்சன ராயப்மபட்சட ேருத்துவேசனயில் ஒரு ஆராய்ச்ைி 
நடக்கிறது. இது 2 வசக நீரிழிவு மநாயாளிகளுக்கு ேிப்பிட் சுயவிவரம் 
ேற்றும் கல்லீரல் பையல்பாட்டு மைாதசன ஆகியவற்றிற்கு 
இசடமயயான பதாடர்பு. வசக 2 டிஸ்ேிபிடிேியா, இன்சுேின் தடுப்பு 
ேற்றும் அல்ோத ேது பகாழுப்பு கல்லீரல் மநாய் (NAFLD) 
பதாடர்புசடயது. சடப் 2 DM இன் உயர் இரத்த அழுத்தம் தூண்டப்பட்ட 
சைப்பர்ஜிைிேியாவின் விசளவாக, ேிபிட் சுயவிவரம், 
ஆக்ஸிஜமனற்ற அழுத்தம் குறிப்பிகள் ேற்றும் NAFLD ேற்றும் ைாதாரண 
கல்லீரல் பையல்பாட்டு மைாதசனகள் உள்ள மநாயாளிகளுக்கு அழற்ைி 
விசளவிக்கின்றன. இரத்த குளுக்மகாஸ் அளவுகள் ேற்றும் கல்லீரல் 
பையல்பாட்டு மைாதசனகளின் வழக்கோன கண்காணிப்பு கல்லீரல் 
பகாழுப்பு மைேிப்சபக் குசறப்பதற்கும், ேது ைார்பு ஸ்டீடாமபபாட்ட்டிஸ் 
(என்ஏஎச்), ஈரல் அழற்ைி அல்ேது கல்லீரல் புற்றுமநாய் ேற்றும் 
அவற்றின் பதாடர்புசடய ைிக்கல்களின் வளர்ச்ைிசயத் தவிர்க்கவும் 
மநாயாளிகள் இந்த வசகக்கு பரிந்துசரக்கப்பட மவண்டும்.                         
இந்த ஆய்வில் பங்மகற்க நாங்கள் விரும்புகிமறாம். இந்த ஆய்வின் 
முடிவுகசள பவளியிடுசகயில், உங்கள் அசடயாளத்சத எந்த 
வசகயிலும் பவளிப்படுத்த ோட்மடாம். இந்த ஆய்வில் பங்மகற்பது 
உங்கள் பைாந்த விருப்பம். நீங்கள் எப்மபாது மவண்டுோனாலும் இந்த 
படிப்பிேிருந்து விேக்கோம். இந்த ஆய்வுகளின் முடிவுகசள நாங்கள் 
உங்களுக்கு பதரிவிப்மபாம். 
 
ஆராய்ச்ைியாளர் சகபயாப்பம்    பங்மகற்பாளர் சகபயாப்பம் 
மததி: 
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MASTER CHART 
SNO AGE SEX ALCOHOLISM FBS PPBS FLP LFT 
USG-FATTY 
LIVER 
1 55 M PRS 124 177 TC-244 TGL-188   
TP-6 ALB-3.6 GLB-2.4 BIL-0.9 ALT-30 
AST-28 PRS 
2 33 F ABS  211 167 TC-188 TGL-99  
TP-6 ALB-3.6 GLB-2.4 BIL-1.2 ALT-32 
AST-26 ABS  
3 44 F ABS  134 155 TC-222 TGL-156  TP-7 ALB-4 GLB-3 BIL-1 ALT-50 AST-44 PRS 
4 48 F ABS  144 133 TC-180 TGL-90  TP-7 ALB-4 GLB-3 BIL-1 ALT-50 AST-44 PRS 
5 46 M ABS  96 188 TC-178 TGL-122  TP-6 ALB-4 GLB-2 BIL-1 ALT-62 AST-44 PRS 
6 70 M ABS  188 210 TC-244 TGL-156  
TP-7.5 ALB-4 GLB-3.5 BIL-.9 ALT-22 
AST-34 ABS  
7 81 F ABS  166 200 TC-188 TGL-152 
TP-6 ALB-4 GLB-2 BIL-1.2 ALT-62 AST-
44 PRS 
8 44 M ABS  110 166 TC-210 TGL-156  TP-5 ALB-3 GLB-2 BIL-1 ALT-52 AST-54 PRS 
9 39 M ABS  128 154 TC-243 TGL-186  
TP-6.4 ALB-4 GLB-2.4 BIL-.8 ALT-48 
AST-44 PRS 
10 80 M ABS  112 198 TC-188 TGL-110 
TP-8 ALB-5 GLB-3 BIL-1.3 ALT-33 AST-
29 ABS  
11 57 M ABS  234 155 TC-212 TGL-162 TP-6 ALB-3 GLB-3 BIL-1 ALT-52 AST-48 PRS 
12 55 M ABS  122 144 TC-188 TGL-88 
TP-6.6 ALB-4 GLB-2.6 BIL-1.3 ALT-34 
AST-30 ABS  
13 45 F ABS  134 156 TC-242 TGL-167 TP-6 ALB-4 GLB-2 BIL-1 ALT-66 AST-54 PRS 
14 67 F ABS  156 177 TC-222 TGL-150 TP-7 ALB-4 GLB-3 BIL-1 ALT-54 AST-44 PRS 
15 41 M ABS  178 174 TC-242 TGL-170 
TP-6 ALB-4 GLB-2 BIL-.9 ALT-55 AST-
52 PRS 
16 42 F ABS  110 164 TC-188 TGL-110 TP-6 ALB-4 GLB-2 BIL-1 ALT-32 AST-36 ABS  
17 54 F ABS  99 124 TC-214 TGL-144 
TP-5 ALB-3 GLB-2 BIL-1.1 ALT-48AST-
52 PRS 
18 38 M ABS  98 164 TC-194 TGL-111 
TP-6 ALB-3 GLB-3 BIL-.8 ALT-38 AST-
28 ABS  
19 39 F ABS  96 177 TC-208 TGL-148 TP-7 ALB-4 GLB-3 BIL-1 ALT-66 AST-54 PRS 
20 40 F ABS  124 188 TC-254 TGL-190 TP-6 ALB-4 GLB-2 BIL-1 ALT-88 AST-66 PRS 
21 47 M ABS  111 177 TC-344 TGL-192 
TP-6.4 ALB-4 GLB-2.4 BIL-1.1 ALT-56 
AST-68 PRS 
22 47 M ABS  106 144 TC-164 TGL-100 TP-6 ALB-4 GLB-2 BIL-1 ALT-34 AST-28 ABS  
23 48 M ABS  103 166 TC-182 TGL-94 TP-6 ALB-4 GLB-2 BIL-1 ALT-28 AST-36 ABS  
24 38 F ABS  107 188 TC-226 TGL-146 
TP-6 ALB-3 GLB-3 BIL-.9 ALT-52 AST-
96 PRS 
25 45 M ABS  104 122 TC-262 TGL-168 
TP-7 ALB-3.8 GLB-3.2 BIL-1 ALT-48 
AST-44 PRS 
26 48 M ABS  106 143 TC-212 TGL-154 
TP-6.6 ALB-4 GLB-2.6 BIL-1.3 ALT-55 
AST-66 PRS 
27 49 F ABS  106 196 TC-164 TGL-98 TP-6 ALB-4 GLB-2 BIL-1 ALT-24 AST-32 ABS  
28 56 F ABS  110 188 TC-198 TGL-110 
TP-6.6 ALB-3.8 GLB-2.8 BIL-.6 ALT-32 
AST-34 ABS  
29 58 F ABS  123 189 TC-234 TGL-160 TP-6 ALB-4 GLB-2 BIL-1 ALT-56 AST-88 PRS 
30 59 M ABS  111 142 TC-258 TGL-154 
TP-7.4 ALB-5 GLB-2.4 BIL-1 ALT-64 
AST-54 PRS 
31 42 M ABS  124 166 TC-210 TGL-142 
TP-7 ALB-4 GLB-3 BIL-.9 ALT-48 AST-
54 PRS 
32 44 F ABS  100 178 TC-202 TGL-148 TP-6 ALB-4GLB-2 BIL-1 ALT-44 AST-50 PRS 
33 38 F ABS  98 124 TC-168 TGL-100 
TP-6.6 ALB-4 GLB-2.6 BIL-1.1 ALT-28 
AST-34 ABS  
34 66 F ABS  112 188 TC-241 TGL-158 
TP-7 ALB-4 GLB-3 BIL.7  ALT-42 AST-
64 PRS 
35 54 F ABS  126 196 TC-210 TGL-148 TP-5 ALB-3 GLB-2 BIL.9 ALT-40 AST-44 PRS 
36 55 M ABS  132 222 TC-168 TGL-100 
TP-5.5 ALB-3 GLB-2.5 BIL-1 ALT-30 
AST-32 ABS  
37 45 F ABS  111 166 TC-288 TGL-160 TP-7 ALB-4 GLB-3 BIL-.9ALT-52 AST-48 PRS 
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38 67 M ABS  142 210 TC-198 TGL-156 
TP-7.4 ALB-4 GLB-3.4 BIL-.8 ALT-28 
AST-24 ABS  
39 64 M ABS  166 256 TC-212 TGL-156 
TP-6 ALB-4 GLB-2 BIL-1.1  ALT-49 AST-
44 PRS 
40 43 M ABS  112 156 TC-202 TGL-152 
TP-7 ALB-4 GLB-3 BIL-.9 ALT-54 AST-
58 PRS 
41 42 F ABS  106 136 TC-210 TGL-132 TP-6.8 ALB-4 GLB-2.8 ALT-66 AST-54 PRS 
42 54 M ABS  86 118 TC-196 TGL-112 
TP-7 ALB-3.8 GLB-3.2 BIL-1.2 ALT-22 
AST-26 ABS  
43 55 F ABS  142 180 TC-188 TGL-124 
TP-5.5 ALB-3 GLB-2.5 BIL-.7 ALT-27 
AST-30 ABS  
44 38 F ABS  124 168 TC-214 TGL-162 TP-7 ALB-4 GLB-3 BIL-1 ALT-56 AST-58 PRS 
45 55 M ABS  120 144 TC-178 TGL-98 
TP-6 ALB-4 GLB-2 BIL-.8 ALT-33 AST-
31 ABS  
46 44 M ABS  130 210 TC-208 TGL-154 
TP-7 ALB-4 GLB-3 BIL-.8 ALT-45 AST-
44 PRS 
47 74 M ABS  100 160 TC-294 TGL-160 
TP-7.4 ALB-4 BIL-1 GLB-3.4 ALT-49 
AST-57 PRS 
48 56 F ABS  96 120 TC-232 TGL-148 
TP-7 ALB-4 GLB-3 BIL-1.3 ALT-40 AST-
46 PRS 
49 64 F ABS  92 112 TC-216 TGL-168 
TP-5 ALB-3 GLB-2 BIL-1.2  ALT-49 AST-
52 PRS 
50 66 M ABS  112 246 TC-210 TGL-144 
TP-7 ALB-3.6 GLB-3.4 BIL-1.1 ALT-47 
AST-50 PRS 
51 82 F ABS  118 167 TC-180 TGL-98 
TP-7 ALB-4 GLB-3 BIL-.8 ALT-22 AST-
29 ABS  
52 39 M ABS  116 158 TC-242 TGL-170 
TP-6.4 ALB-4 GLB-2.4 BIL-.9 ALT-55 
AST-58 PRS 
53 40 M PRS 154 298 TC-166 TGL-88 TP-7 ALB-4 GLB-3 BIL-1 ALT-30 AST-21 ABS  
54 49 F ABS  126 180 TC-198 TGL-144 
TP-6.6 ALB-3.6 GLB-3 BIL-1.1  ALT-46 
AST-52 PRS 
55 53 F ABS  98 166 TC-186 TGL-112 
TP-6 ALB-4 GLB-2 BIL-1 ALT-28 GLB-
24 ABS  
56 48 F ABS  74 100 TC-216 TGL-152 
TP-5.5 ALB-3.5 GLB-2BIL-1.1  ALT-44 
AST-55 PRS 
57 44 M ABS  106 172 TC-222 TGL-158 
TP-7 ALB-4 GLB-3 BIL-1.1  ALT-58 AST-
49 PRS 
58 57 M PRS 119 174 TC-178 TGL-100 TP-6 ALB-4 GLB-2 BIL-1 ALT-29 AST-27 ABS  
59 58 F ABS  99 134 TC-244 TGL-178 
TP-7 ALB-3.9 GLB-3.1 BIL-.8 ALT-49 
AST-58 PRS 
60 65 M ABS  98 148 TC-194 TGL-111 
TP-7 ALB-4 GLB-3 BIL-.9 ALT-26 AST-
22 ABS  
   
            
61 46 F ABS  99 178 TC-188 TGL-134 TP-6 ALB-4 GLB-2 BIL-1 ALT-25 AST-30 ABS  
62 58 F ABS  110 154 TC-212 TGL-156 
TP-7 ALB-4 GLB-3 BIL-1.2 ALT-44 AST-
48 PRS 
63 42 M PRS 112 136 TC-222 TGL-167 
TP-6.6 ALB-4 GLB-2.6 BIL-.7 ALT-45 
AST-48 PRS 
64 41 M ABS  78 120 TC-200 TGL-152 
TP-6 ALB-4 GLB-2 BIL-.9 ALT-46 AST-
52 PRS 
65 57 F ABS  134 188 TC-168 TGL-100 
TP-5 ALB-3 GLB-2 BIL-1.4 ALT-25 AST-
30 ABS  
66 68 M ABS  98 158 TC-203 TGL-150 
TP-6 ALB-3.5 GLB-2.5 BIL-.9 ALT-44 
AST-42 PRS 
67 61 M PRS 96 167 TC-212 TGL-154 
TP-6.4 ALB-4 GLB-2.4 BIL-.8  ALT-49 
AST-53 PRS 
68 54 M ABS  88 155 TC-210 TGL-154 
TP-6 ALB-3.8 GLB-2.2 BIL-.8 ALT-54 
AST-58 PRS 
69 52 M ABS  113 134 TC-243 TGL-176 
TP-6 ALB-4 GLB-2 BIL-1.3 ALT-46 AST-
50 PRS 
70 49 F ABS  188 233 TC-190 TGL-120 
TP-7 ALB-4 GLB-3BIL-1.2  ALT-25 AST-
31 ABS  
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71 42 F ABS  142 210 TC-202 TGL-148 
TP-7 ALB-4.5 GLB-2.5 BIL-1.1 ALT-42 
AST-39 PRS 
72 39 M ABS  118 188 TC-166 TGL-90 
TP-5 ALB-3 GLB-2 BIL-.8  ALT-26 AST-
22 ABS  
73 47 F ABS  102 174 TC-219 TGL-155 
TP-7 ALB-4 GLB-3 BIL-.7 ALT-45 AST-
48 PRS 
74 46 M ABS  118 173 TC-198 TGL-98 
TP-6 ALB-4 GLB-2 BIL-1.1 ALT-18 AST-
30 ABS  
75 58 F ABS  100 180 TC-218 TGL-156 
TP-5 ALB-3 GLB-2 BIL-1.4 ALT-55 AST-
62 PRS 
76 57 F ABS  90 138 TC-186 TGL-96 
TP-7 ALB-5 GLB-2 BIL-1.4 ALT-22 AST-
28 ABS  
77 54 F ABS  88 136 TC-244 TGL-164 
TP-6.4 ALB-4 GLB-2.4 BIL-.6  ALT-44 
AST-46 PRS 
78 51 M ABS  97 110 TC-224 TGL-159 
TP-7 ALB-5 GLB-2 BIL-.9 ALT-48 AST-
52 PRS 
79 64 M ABS  119 179 TC-190 TGL-122 
TP-7.4 ALB-4 GLB-3.4 BIL-.8 ALT-25 
AST-30 ABS  
80 62 M PRS 122 168 TC-186 TGL-100 
TP-8 ALB-5 GLB-3 BIL-.8 ALT-26 AST-
18 ABS  
81 68 F ABS  97 154 TC-218 TGL-154 
TP-6 ALB-3.5  BIL-1.3 GLB-2.5 ALT-66 
AST-54 PRS 
82 66 F ABS  134 168 TC-178 TGL-112 
TP-5 ALB-3 BIL-1.1  GLB-2 ALT-25 AST-
23 ABS  
83 47 M ABS  89 155 TC-211 TGL-157 
TP-6 ALB-4 GLB-2 BIL-1  ALT-45 AST-
51 PRS 
84 43 M ABS  108 180 TC-234 TGL-158 
TP-5.5 ALB-3.5 GLB-2 BIL-1.1 ALT-49 
AST-51 PRS 
85 40 F ABS  127 159 TC-200 TGL-148 
TP-7 ALB-4 GLB-3 BIL-.5 ALT-46 AST-
50 PRS 
86 57 F ABS  108 158 TC-176 TGL-98 
TP-6 ALB-4 GLB-2 BIL-.9N ALT-25 AST-
20 ABS  
87 58 F ABS  107 167 TC-216 TGL-164 
TP-6.5 ALB-4 GLB-2.5 BIL-1 ALT-55 
AST-66 PRS 
88 43 M ABS  94 169 TC-168 TGL-100 
TP-7 ALB-4 GLB-3 BIL-.7 ALT-20 AST-
18 ABS  
89 49 M ABS  98 188 TC-210 TGL-154 
TP-7 ALB-4 GLB-3 BIL-1  ALT-44 AST-
50 PRS 
90 50 F ABS  99 172 TC-288 TGL-190 
TP-8 ALB-5 GLB-3 BIL-1.3 ALT-46 AST-
54 PRS 
   
            
91 55 F ABS  117 157 TC-212 TGL-154 
TP-5 ALB-3.5 BIL-1 GLB-2 ALT-48 AST-
55 PRS 
92 45 M ABS  102 159 TC-212 TGL-156 
TP-5.5 ALB-3.5 GLB-2 BIL-.8 ALT-44 
AST-49 PRS 
93 44 M ABS  124 198 TC-234 TGL-154 
TP-6 ALB-3.5 GLB-2.5 BIL-.7 ALT-48 
AST-50 PRS 
94 48 F ABS  111 210 TC-212 TGL-150 
TP-6 ALB-3.5 GLB-2.5 BIL-1.1 ALT-41 
AST-55 PRS 
95 57 F ABS  96 145 TC-219 TGL-159 
TP-7 ALB-4.5 GLB-2.5BIL-1.2  ALT-47 
AST-58 PRS 
96 58 M PRS 88 157 TC-152 TGL-88 
TP-5.5 ALB-3.5 BIL-1.3 GLB-2 ALT-18 
AST-22 ABS  
97 59 M ABS  107 169 TC-162 TGL-90 
TP-7 ALB-4 GLB-3 BIL-1.4 ALT-31 AST-
29 ABS  
98 60 F ABS  110 178 TC-246 TGL-167 
TP-6 ALB-4 GLB-2 BIL-1.7 ALT-49 AST-
52 PRS 
99 66 M ABS  111 180 TC-182 TGL-100 
TP-7 ALB-4 GLB-3 BIL-.8  ALT-22 AST-
29 PRS 
100 41 F ABS  94 271 TC-272 TGL-198 
TP-6 ALB-3.5 GLB-2.5 BIL-1 ALT-48 
AST-62 PRS 
 
